Iovance Biotherapeutics announced that Australia's TGA approved Amtagvi (lifileucel) for previously treated advanced melanoma, marking the company's third marketing authorization for the therapy. This approval addresses a significant market need in Australia, which has the highest melanoma incidence globally, and strengthens Iovance's commercial position in the TIL therapy space.